Collection of Bone Marrow and Peripheral Blood for Testing of Notch-induced Natural Killer Cell Activity
- To collect normal and malignant cells in bone marrow and peripheral blood samples from
patients with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous
leukemia, or multiple myeloma and from patients with no malignancy to use as target
cells in cytotoxicity assays.
- To collect information about HLA type and immunophenotype of malignant cells as
determined by clinical flow cytometry.
OUTLINE: Bone marrow aspirates and/or peripheral blood samples are collected and used as
target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells
as the effector cells, to determine whether N-NK cells are capable of killing malignant
cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine
which NK cell receptors are responsible for malignant cell recognition and killing.
Information about HLA type and immunophenotype of the malignant cells is collected from the
patient's medical record.
Observational Model: Case Control, Time Perspective: Prospective
Collection of normal and malignant cells to use as target cells in cytotoxicity assays
We anticipate collecting approximately 30 samples in total, over a 1-2 year period.
Rose Beck, MD, PhD
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
United States: Institutional Review Board
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|